Research Analysts’ updated eps estimates for Tuesday, January 14th:
Barrick Gold (TSE:ABX) (NYSE:ABX) had its buy rating reissued by analysts at TD Cowen. The firm currently has a C$36.00 price target on the stock.
Akebia Therapeutics (NASDAQ:AKBA) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $7.50 price target on the stock.
Abercrombie & Fitch (NYSE:ANF) had its outperform rating reaffirmed by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $190.00 price target on the stock.
Anixa Biosciences (NASDAQ:ANIX) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $10.00 price target on the stock.
Apellis Pharmaceuticals (NASDAQ:APLS) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $57.00 target price on the stock.
Appian (NASDAQ:APPN) had its sector weight rating reiterated by analysts at KeyCorp.
argenx (NASDAQ:ARGX) had its buy rating reiterated by analysts at Truist Financial Co.. Truist Financial Co. currently has a $700.00 price target on the stock, up from their previous price target of $660.00.
argenx (NASDAQ:ARGX) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $717.00 price target on the stock, up from their previous price target of $670.00.
Artelo Biosciences (NASDAQ:ARTL) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $6.00 target price on the stock.
Alphatec (NASDAQ:ATEC) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $20.00 target price on the stock.
Bio-Rad Laboratories (NYSE:BIO) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $481.00 price target on the stock.
Biomea Fusion (NASDAQ:BMEA) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $40.00 price target on the stock.
BP (NYSE:BP) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada.
Perspective Therapeutics (NYSE:CATX) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $16.00 price target on the stock.
CareDx (NASDAQ:CDNA) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $26.00 price target on the stock.
Chegg (NYSE:CHGG) had its underweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $1.25 target price on the stock, down from their previous target price of $2.00.
Choice Hotels International (NYSE:CHH) had its underweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $129.00 price target on the stock, down from their previous price target of $145.00.
California Resources (NYSE:CRC) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $70.00 price target on the stock.
Charles River Laboratories International (NYSE:CRL) had its outperform rating reiterated by analysts at William Blair.
CRISPR Therapeutics (NASDAQ:CRSP) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $84.00 target price on the stock.
Corvus Pharmaceuticals (NASDAQ:CRVS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $11.00 target price on the stock.
CyberArk Software (NASDAQ:CYBR) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $360.00 target price on the stock.
Cytokinetics (NASDAQ:CYTK) had its market outperform rating reissued by analysts at JMP Securities. The firm currently has a $78.00 price target on the stock.
Delcath Systems (NASDAQ:DCTH) had its buy rating reissued by analysts at HC Wainwright. They currently have a $22.00 price target on the stock.
Dyne Therapeutics (NASDAQ:DYN) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $45.00 target price on the stock.
Ekso Bionics (NASDAQ:EKSO) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $9.00 target price on the stock.
Elevation Oncology (NASDAQ:ELEV) had its buy rating reissued by analysts at HC Wainwright. They currently have a $6.00 price target on the stock.
Element Solutions (NYSE:ESI) had its neutral rating reaffirmed by analysts at Bank of America Co.. The firm currently has a $28.00 price target on the stock, down from their previous price target of $32.00.
European Wax Center (NASDAQ:EWCZ) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. They currently have a $6.00 target price on the stock.
Chesapeake Energy (NASDAQ:EXE) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $116.00 target price on the stock.
Five Below (NASDAQ:FIVE) had its market perform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $115.00 price target on the stock.
Fortinet (NASDAQ:FTNT) had its market perform rating reaffirmed by analysts at Raymond James.
General Dynamics (NYSE:GD) had its neutral rating reissued by analysts at Robert W. Baird. Robert W. Baird currently has a $283.00 price target on the stock, down from their previous price target of $345.00.
The Gym Group (LON:GYM) had its buy rating reaffirmed by analysts at Shore Capital.
Hostelworld Group (LON:HSW) had its buy rating reissued by analysts at Shore Capital.
ICON Public (NASDAQ:ICLR) had its outperform rating reaffirmed by analysts at William Blair.
Incyte (NASDAQ:INCY) had its market perform rating reaffirmed by analysts at JMP Securities.
Inogen (NASDAQ:INGN) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Inspired (LON:INSE) had its house stock rating reaffirmed by analysts at Shore Capital.
Intra-Cellular Therapies (NASDAQ:ITCI) had its neutral rating reaffirmed by analysts at Piper Sandler. They currently have a $132.00 target price on the stock, up from their previous target price of $107.00.
OrthoPediatrics (NASDAQ:KIDS) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $42.00 price target on the stock.
Lantheus (NASDAQ:LNTH) had its market outperform rating reissued by analysts at JMP Securities. JMP Securities currently has a $112.00 target price on the stock.
Las Vegas Sands (NYSE:LVS) had its equal weight rating reaffirmed by analysts at Morgan Stanley. They currently have a $51.00 price target on the stock, down from their previous price target of $54.00.
Macy’s (NYSE:M) had its market perform rating reissued by analysts at Telsey Advisory Group. The firm currently has a $17.00 target price on the stock.
Merit Medical Systems (NASDAQ:MMSI) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $109.00 price target on the stock.
MicroStrategy (NASDAQ:MSTR) had its buy rating reissued by analysts at Benchmark Co.. They currently have a $650.00 price target on the stock.
M.T.I Wireless Edge (LON:MWE) had its house stock rating reissued by analysts at Shore Capital.
NewAmsterdam Pharma (NASDAQ:NAMS) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $48.00 target price on the stock.
NovoCure (NASDAQ:NVCR) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $38.00 target price on the stock.
ORIC Pharmaceuticals (NASDAQ:ORIC) had its overweight rating reiterated by analysts at Cantor Fitzgerald.
Palo Alto Networks (NASDAQ:PANW) had its market outperform rating reissued by analysts at JMP Securities. JMP Securities currently has a $208.00 target price on the stock.
Pacira BioSciences (NASDAQ:PCRX) had its sector perform rating reiterated by analysts at Royal Bank of Canada. The firm currently has a $18.00 price target on the stock.
Pegasystems (NASDAQ:PEGA) had its overweight rating reiterated by analysts at KeyCorp. KeyCorp currently has a $118.00 price target on the stock.
Precigen (NASDAQ:PGEN) had its market outperform rating reiterated by analysts at JMP Securities. JMP Securities currently has a $5.00 target price on the stock.
Plymouth Industrial REIT (NYSE:PLYM) had its market outperform rating reissued by analysts at JMP Securities. The firm currently has a $27.00 price target on the stock.
D-Wave Quantum (NYSE:QBTS) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $8.00 target price on the stock.
Quantum-Si (NASDAQ:QSI) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $5.50 price target on the stock.
Rigel Pharmaceuticals (NASDAQ:RIGL) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $57.00 target price on the stock.
Relay Therapeutics (NASDAQ:RLAY) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $16.00 price target on the stock.
RumbleOn (NASDAQ:RMBL) had its neutral rating reaffirmed by analysts at DA Davidson. They currently have a $5.00 price target on the stock, down from their previous price target of $7.50.
Range Resources (NYSE:RRC) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $40.00 price target on the stock.
Sight Sciences (NASDAQ:SGHT) had its hold rating reissued by analysts at Needham & Company LLC.
Sunstone Hotel Investors (NYSE:SHO) had its underweight rating reissued by analysts at Morgan Stanley. Morgan Stanley currently has a $10.00 price target on the stock.
Sono-Tek (NASDAQ:SOTK) had its outperform rating reiterated by analysts at Northland Securities. The firm currently has a $7.50 price target on the stock, down from their previous price target of $10.00.
Sarepta Therapeutics (NASDAQ:SRPT) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $202.00 price target on the stock.
Trip.com Group (NASDAQ:TCOM) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $80.00 target price on the stock.
ThredUp (NASDAQ:TDUP) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Tempus AI (NASDAQ:TEM) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $56.00 price target on the stock.
Tenaya Therapeutics (NASDAQ:TNYA) had its buy rating reissued by analysts at HC Wainwright. They currently have a $18.00 target price on the stock.
TTM Technologies (NASDAQ:TTMI) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $30.00 target price on the stock.
Voya Financial (NYSE:VOYA) had its equal weight rating reaffirmed by analysts at Wells Fargo & Company. They currently have a $76.00 target price on the stock, down from their previous target price of $87.00.
Ventyx Biosciences (NASDAQ:VTYX) had its neutral rating reiterated by analysts at HC Wainwright.
VYNE Therapeutics (NASDAQ:VYNE) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $5.75 price target on the stock.
X4 Pharmaceuticals (NASDAQ:XFOR) had its buy rating reissued by analysts at HC Wainwright. They currently have a $1.50 target price on the stock.
Zevia PBC (NYSE:ZVIA) had its market perform rating reiterated by analysts at Telsey Advisory Group. The firm currently has a $4.00 price target on the stock.
Receive News & Ratings for Barrick Gold Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barrick Gold Co and related companies with MarketBeat.com's FREE daily email newsletter.
